Home / Biosimilars / General / Biosimilars Forum launched

Biosimilars Forum launched Posted 08/05/2015

A group of biosimilars developers in the US announced on 5 May 2015 the launch of a joint initiative to promote biosimilars in the form of the Biosimilars Forum.

The forum was developed by 11 brand-name and generics companies all involved in developing biosimilars as ‘the first nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States’.

The companies behind the launch represent the majority of companies with the most significant US biosimilars development portfolios and include Actavis, Amgen, Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Hospira, Merck, Pfizer, Samsung, Sandoz, and Teva.

The Biosimilars Forum intends to ‘provide evidence-based information to educate and advocate for public policies and practices that encourage access, awareness and adoption of biosimilars’.

The forum points to the significant benefits of biosimilars, which have been used in the European Union since 2006. They also highlight an analysis conducted by the Congressional Budget Office, which estimated that the introduction of biosimilars would reduce drug spending by roughly US$25 billion over 10 years, saving the federal government nearly US$6 billion.

The forum will submit a public statement on 7 May 2015 to the Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System to address the need for appropriate coding for biosimilars.

Related article
GPhA launches Biosimilars Council

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Biosimilars Forum

Comments (0)